Abstract: An object of the present disclosure is to provide a more effective therapeutic method in cancer therapy using the tumor immune mechanism. An object of the present disclosure is to provide a drug that enhances the production of antitumor, inflammatory, and anti-inflammatory cytokines as the more effective tumor immune therapy. Alternatively, an object of the present disclosure is to provide a drug that increases tumor-infiltrating lymphocytes as the more effective tumor immune therapy. An antitumor agent to be administered in combination with an anti-PD-1 antibody, an anti-PD-L1 antibody, and/or an anti-CTLA-4 antibody, which are immune checkpoint inhibitors (ICIs), comprising: ubenimex as an active ingredient. The combination therapy of ubenimex and an ICI improves the tumor immune function as compared with the use of each of these alone, and brings many benefits to the treatment of malignant tumors.

Abstract: Provided are a method for evaluating evenness of suplatast tosilate crystals; stable suplatast tosilate crystals exhibiting evenness in optical purity; and a method for producing the suplatast tosilate crystals. The method for evaluating evenness of suplatast tosilate crystals includes: (a) a step of adding a solvent to suplatast tosilate crystals to thereby dissolve 3% or less of the crystals in the solvent, and subjecting a portion of the supernatant of the resultant suspension to optical purity measurement, and (b) a step of adding a solvent to the remaining suspension to thereby dissolve the entirety of the suspension in the solvent, and subjecting a portion of the resultant solution to optical purity measurement, wherein the optical purity as measured in the step (a) is compared with the optical purity as measured in the step (b). The suplatast tosilate crystals exhibits excellent evenness and thermal stability. The method for producing the suplatast tosilate crystals is also provided.

Abstract: Provided are a method for evaluating evenness of suplatast tosilate crystals; stable suplatast tosilate crystals exhibiting evenness in optical purity; and a method for producing the suplatast tosilate crystals. The method for evaluating evenness of suplatast tosilate crystals includes: (a) a step of adding a solvent to suplatast tosilate crystals to thereby dissolve 30 or less of the crystals in the solvent, and subjecting a portion of the supernatant of the resultant suspension to optical purity measurement, and (b) a step of adding a solvent to the remaining suspension to thereby dissolve the entirety of the suspension in the solvent, and subjecting a portion of the resultant solution to optical purity measurement, wherein the optical purity as measured in the step (a) is compared with the optical purity as measured in the step (b). The suplatast tosilate crystals exhibits excellent evenness and thermal stability. The method for producing the suplatast tosilate crystals is also provided.

Abstract: Provided are a method for evaluating evenness of suplatast tosilate crystals; stable suplatast tosilate crystals exhibiting evenness in optical purity; and a method for producing the suplatast tosilate crystals. The method for evaluating evenness of suplatast tosilate crystals includes: (a) a step of adding a solvent to suplatast tosilate crystals to thereby dissolve 3% or less of the crystals in the solvent, and subjecting a portion of the supernatant of the resultant suspension to optical purity measurement, and (b) a step of adding a solvent to the remaining suspension to thereby dissolve the entirety of the suspension in the solvent, and subjecting a portion of the resultant solution to optical purity measurement, wherein the optical purity as measured in the step (a) is compared with the optical purity as measured in the step (b). The suplatast tosilate crystals exhibits excellent evenness and thermal stability. The method for producing the suplatast tosilate crystals is also provided.

Abstract: Provided are a method for evaluating evenness of suplatast tosilate crystals; stable suplatast tosilate crystals exhibiting evenness in optical purity; and a method for producing the suplatast tosilate crystals. The method for evaluating evenness of suplatast tosilate crystals includes: (a) a step of adding a solvent to suplatast tosilate crystals to thereby dissolve 3% or less of the crystals in the solvent, and subjecting a portion of the supernatant of the resultant suspension to optical purity measurement, and (b) a step of adding a solvent to the remaining suspension to thereby dissolve the entirety of the suspension in the solvent, and subjecting a portion of the resultant solution to optical purity measurement, wherein the optical purity as measured in the step (a) is compared with the optical purity as measured in the step (b). The suplatast tosilate crystals exhibits excellent evenness and thermal stability. The method for producing the suplatast tosilate crystals is also provided.

Abstract: Provided are a suplatast tosilate crystal showing characteristic peaks in powder X-ray diffraction diffraction angles (20±0.1°) of 5.6°, 9.0°, 11.0°, 15.3°, 16.5°, 17.2°, 17.9°, 19.2°, 19.9°, and 21.5°; and a preparation process of the crystal. Owing to merits such as fluctuation-free optically active substance ratio, low hygroscopicity and high storage stability, the suplatast tosilate crystal of the present invention can be mass-produced easily and, at the same time, is advantageous in drug preparation quality management. It is thus excellent as raw material for pharmaceuticals.

Abstract: Provided are a suplatast tosilate crystal showing characteristic peaks in powder X-ray diffraction at diffraction angles (2&thgr;+0.1°) of 5.6°, 9.0°, 11.0°, 15.3°, 16.5°, 17.2°, 17.9°, 19.2°, 19.9° and 21.5°; and a preparation process of the crystal.

Abstract: A protein composition derived from sesame seed is disclosed, which contains 40-95% by weight of crude proteins, 1-50% by weight of carbohydrate, 0-5% by weight of fat, 0-1% by weight of fiber, and 0.2-3% by weight of physiologically active substances derived from sesame seed, based on the dry weight of the composition and which is characterized in that when the protein composition is suspended at room temperature in pure water of pH 7 at a concentration of 5% by weight, not less than 80% by weight of the protein composition is dissolved in the pure water. A foodstuff or a cosmetic article containing the protein composition is also disclosed.

Abstract: The invention provides a method of textile printing using microorganisms with less limitation to dyes with less damage on base materials, and with less blurring of color borders. The method is capable of producing a complex, fine pattern; capable of realizing colored discharge printing with brilliant colors; and capable of readily producing an ombre pattern. The invention also provides a microorganism for decolorization of azo-system dye and use in the textile printing method. In accordance with the invention, textile printing is carried out by coating a solution or paste (which may contain a dye) containing a bacterial strain Bacillus OY1-2 of genus Bacillus (Deposit Number: FERM 13118), in a desirable pattern on the cloth dyed with an azo dye (which may include a non-azo dye), subsequently proliferating or acting the bacterial strain while keeping the strain in a wet state, and to entirely or partially metabolize the azo dye to eliminate or decrease the coloring of the azo dye for textile printing.

Abstract: The invention provides a method of textile printing using microorganisms with less limitation to dyes with less damage on base materials, and with less blurring of color borders. The method is capable of producing a complex, fine pattern; capable of realizing colored discharge printing with brilliant colors; and capable of readily producing an ombre pattern. The invention also provides a microorganism for decolorization of azo-system dye and use in the textile printing method.

Abstract: The invention provides a method of textile printing using microorganisms with less limitation to dyes, with less damage on base materials, and with less blurring of color borders. The method is capable of producing a complex, fine pattern; capable of realizing colored discharge printing with brilliant colors; and capable of readily producing an ombre pattern. The invention also provides a microorganism for decolorization of azo-system dye and use in the textile printing method.